Glufosfamide Combination Therapies for Cancer
AssigneeEleison Pharmaceuticals LLC
InventorsForrest H. Anthony, Edwin J. Thomas, Matthew Parris
Life of this patent
Estimating the term…
Abstract
The invention provides compositions and methods for treating cancer with glufosfamide in combination with an inhibitor of sodium-glucose transporter type 2 (SGLT2) to block the uptake of glucose in the proximal tubules of the kidneys to decrease renal toxicity. The invention relates to the fields of biomedicine, pharmacology, and molecular biology.
Claims11
A combination therapy comprising:
- (i) an inhibitor of a kidney glucose transporter protein
- (ii) an effective amount of a glucose-conjugated chemotherapeutic drug such as glufosfamide.
A method of treating cancer in a patient comprising administering a therapeutically effective amount of glufosfamide in combination with sodium-glucose transporter type 2 inhibitor to a patient in need of a cancer treatment.
A method of treating a patient diagnosed with cancer, said method comprising the steps of:
- (i) administering an agent that inhibits the absorption of glucose by the kidneys to said patient;
- and
- (ii) administering a therapeutically effective amount of glucose-conjugated chemotherapeutic agent to said patient.
Dependencies are inferred from the claim text.